hVIVO’s (HVO) “Buy” Rating Reaffirmed at Peel Hunt

hVIVO (LON:HVO)‘s stock had its “buy” rating reissued by analysts at Peel Hunt in a research note issued to investors on Monday, Digital Look reports. They presently have a GBX 14 price objective on the stock. Peel Hunt’s price target suggests a potential upside of 136.09% from the stock’s previous close.

hVIVO Trading Up 0.5%

Shares of LON HVO opened at GBX 5.93 on Monday. The firm has a market cap of £40.82 million, a PE ratio of -3.33 and a beta of 1.69. The company has a quick ratio of 1.16, a current ratio of 1.21 and a debt-to-equity ratio of 43.38. hVIVO has a twelve month low of GBX 4.30 and a twelve month high of GBX 11. The business has a fifty day simple moving average of GBX 6.47 and a two-hundred day simple moving average of GBX 7.16.

hVIVO (LON:HVO) last posted its quarterly earnings results on Tuesday, September 15th. The company reported GBX (0.82) EPS for the quarter. hVIVO had a negative net margin of 31.76% and a negative return on equity of 35.13%. Analysts expect that hVIVO will post 1.55 earnings per share for the current fiscal year.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.